Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Hydrocortisone hearings

Executive Summary

Companies with combination drug products containing hydrocortisone acetate and pramoxine hydrochloride have until Oct. 31 to file data and information in support of hearing requests concerning the withdrawal of such products from the market. FDA granted an extension to the original Aug. 31 filing date, set in a July 1 Federal Register notice, after Parke-Davis, Ferndale Labs, Copley Pharmaceutical, and Reed and Carnrick appealed for an end of November filing date.

You may also be interested in...



BMS, Eisai Team Up To Accelerate Development Of Solid-Tumor ADC

The US firm gets development and co-commercial rights to MORAb-202 for $650m up front. BMS joins AstraZeneca, Merck & Co. and Gilead in recent ADC deal-making.

BIO 2021 Notebook: Best Practices For Business Development

The recently concluded BIO annual meeting included several sessions focused on the practice of business development. In this extra edition of our BIO 2021 notebook, Scrip collected observations about best practices for partnerships.

Blueprint Prepares To Take On Novartis In Advanced Systemic Mastocytosis

The company’s rollout plans for Ayvakit appear similar to its approach when it marketed the drug for GIST, with an education plan to help boost sales.

UsernamePublicRestriction

Register

PS014229

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel